Abstract: AIM: to assess the differences in efficacy and safety between risperidone combing antidepressants and single antidepressant in treatment of depression.METHODS: 10 studies meeting ourcriteria were ana-lyzed by based-evidence medicine,comparing the differ-ence in efficacy,effect size(ES),full remission rate and side effects.RESULTS: Hoterogenity test:(1)efficacy,χ²=7.26,d_f=9,P>0.05;(2)safety,χ²=3.41,d_f=2,P>0.05.Comprehensive test:the comprehensive testing result between two groups at 1st,2nd,4th,6th,8th weekend were as following:Z₁=14.19,P<0.01;Z₂=14.00,P<0.01;Z₄=17.40,P<0.01;Z₆=12.10,P<0.01;Z₈=5.94,P<0.01.3.Effect size(ES):The effect size of two groups at 1st,2nd,4th,·1302·Chin J Clin Pharmacol Ther2005 Nov;10(11)6th,8th weekend are all respectively more than 0.5,and intervening effect size between two groups all more than 0.8.4.Efficacy:The full remission rate and significant effective rate of studying groups by fixed effect model and random effect model were highersignificantly than that of control groups,and ineffective rate were significantly low-erthan that of control groups.4.Side effect:No differ-ence in side effects between two groups was found(Z =0.20-1.15,P>0.05).CONCLUSION: It is a bettertherapy of patients with depression,especially treatment-resistant depression,combining antidepressants with lowerdosage of risperidone.

Key words: Antidepressant, Depression, Efficacy, Safety, Meta-analysis, Evidence-based Medication, Risper-idone